早期乳腺癌蒽环类试验(USOR 06-090、NSABP B-46-I/USOR 07132 和 NSABP B-49 [NRG肿瘤学])的长期随访
ABC试验2017年主要联合疗效分析未能证明非蒽环类辅助治疗在高危早期乳腺癌中非劣于蒽环类方案,中位随访3.3年时因无效边界被跨越而提前分析。本报告为中位随访6.9年的最终疗效分析,无侵袭性疾病生存(IDFS)非劣性仍无法宣称,无复发生存间隔倾向蒽环类,激素受体状态异质性检验显著(P=0.02),总生存无差异。
要点
- 中位随访6.9年,非蒽环类方案基于原标准仍未能宣称IDFS非劣于蒽环类方案。
- 无复发生存间隔倾向蒽环类方案,激素受体阴性亚组获益更明显(异质性P=0.02)。
- 总生存无差异,蒽环类方案的复发减少被晚期白血病和非乳腺癌死亡所抵消。
核心结论
- 长期分析显示非蒽环类方案基于原标准仍不能宣称IDFS非劣于蒽环类方案,无复发生存间隔倾向蒽环类,总生存无差异。
研究设计与样本
- ABC试验(USOR 06-090、NSABP B-46-I/USOR 07132、NSABP B-49 [NRG Oncology])的长期随访分析,中位随访6.9年。
- 2017年主要联合疗效分析中位随访3.3年时预设无效边界被跨越,本研究为最终疗效终点分析。
主要发现
- 中位随访6.9年,IDFS长期分析与原结果一致,基于原标准不能宣称非蒽环类方案非劣。
- 无复发生存间隔(排除非乳腺癌死亡)倾向蒽环类方案,激素受体状态异质性检验显著(P=0.02),激素受体阴性队列倾向蒽环类方案。
- 总生存无差异,组间IDFS事件类型回顾提示蒽环类方案减少的癌症复发被晚期白血病和非乳腺癌死亡所抵消。
关键数值与推荐
- 非劣性判定基于原标准,IDFS非劣性未能宣称。
- 无复发生存间隔倾向蒽环类方案,激素受体状态异质性检验P=0.02。
- 总生存无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary joint efficacy analysis of the Anthracyclines in Early Breast Cancer (ABC) trials reported in 2017 failed to demonstrate nonanthracycline adjuvant therapy was noninferior to anthracycline-based regimens in high-risk, early breast cancer. Full analyses of the studies had proceeded when the prespecified futility boundary was crossed at a planned futility analysis for the ability to demonstrate noninferiority of a nonanthracycline regimen with continued follow-up. These results were presented with 3.3 years of median follow-up. This manuscript reports results of the final analyses of the study efficacy end points conducted with 6.9 years of median follow-up. Long-term analysis of invasive disease-free survival (IDFS), the primary end point of the ABC trials, remains consistent with the original results, as noninferiority of the nonanthracycline regimens could not be declared on the basis of the original criteria. The secondary end point of recurrence-free interval, which excluded deaths not due to breast cancer as events, favored anthracycline-based regimens, and tests for heterogeneity were significant for hormone receptor status (P = .02) favoring anthracycline regimens for the hormone receptor-negative cohorts. There was no difference in overall survival, and review of the type of IDFS events in the groups suggested reductions in cancer recurrences achieved with anthracycline regimens were offset by late leukemias and deaths unrelated to breast cancer.
引用
- Geyer CE, Blum JL, Yothers G, et al. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024. PMID: 38335467. doi:10.1200/JCO.23.01428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。